Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.

Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.